FrancophonIA/ELRC3.0 huggingface dataset:
English: Oprymea 1.57 mg prolonged-release tablets 10 prolonged-release tablets: EU/1/08/469/038 30 prolonged-release tablets: EU/1/08/469/039 90 prolonged-release tablets: EU/1/08/469/040 100 prolonged-release tablets: EU/1/08/469/041
Danish: Oprymea 1,57 mg depottabletter 10 depottabletter: EU/1/08/469/038 30 depottabletter: EU/1/08/469/039 90 depottabletter: EU/1/08/469/040 100 depottabletter: EU/1/08/469/041
English: Oprymea 1.57 mg prolonged-release tablets
Danish: Oprymea 1,57 mg depottabletter
English: Each prolonged-release tablet contains 0.26 mg pramipexole (as 0.375 mg pramipexole dihydrochloride monohydrate).
Danish: Hver depottablet indeholder 0,26 mg pramipexol (som 0,375 mg pramipexoldihydrochloridmonohydrat).
English: EU/1/08/469/050 [10 prolonged-release tablets] EU/1/08/469/051 [30 prolonged-release tablets] EU/1/08/469/052 [90 prolonged-release tablets] EU/1/08/469/053 [100 prolonged-release tablets]
Danish: EU/1/08/469/050 [10 depottabletter] EU/1/08/469/051 [30 depottabletter] EU/1/08/469/052 [90 depottabletter] EU/1/08/469/053 [100 depottabletter]
English: EU/1/08/469/006 [20 tablets] EU/1/08/469/007 [30 tablets] EU/1/08/469/008 [60 tablets] EU/1/08/469/009 [90 tablets] EU/1/08/469/010 [100 tablets]
Danish: EU/1/08/469/006 [20 tabletter] EU/1/08/469/007 [30 tabletter] EU/1/08/469/008 [60 tabletter] EU/1/08/469/009 [90 tabletter] EU/1/08/469/010 [100 tabletter]
English: EU/1/08/469/034 [10 prolonged-release tablets] EU/1/08/469/035 [30 prolonged-release tablets] EU/1/08/469/036 [90 prolonged-release tablets] EU/1/08/469/037 [100 prolonged-release tablets]
Danish: EU/1/08/469/034 [10 depottabletter] EU/1/08/469/035 [30 depottabletter] EU/1/08/469/036 [90 depottabletter] EU/1/08/469/037 [100 depottabletter]
English: România KRKA Romania S.R.L., Bucharest
Danish: Malta E. J. Busuttil Ltd.
English: During the first week, the usual dose is 1 tablet Oprymea 0.088 mg once a day (equivalent to 0.088 mg daily):
Danish: I den første uge er dosis oftest 1 tablet Oprymea á 0,088 mg én gang daglig.
English: EU/1/08/469/046 [10 prolonged-release tablets] EU/1/08/469/047 [30 prolonged-release tablets] EU/1/08/469/048 [90 prolonged-release tablets] EU/1/08/469/049 [100 prolonged-release tablets]
Danish: EU/1/08/469/046 [10 depottabletter] EU/1/08/469/047 [30 depottabletter] EU/1/08/469/048 [90 depottabletter] EU/1/08/469/049 [100 depottabletter]
English: Oprymea 0.52 mg prolonged-release tablets Pramipexole
Danish: Oprymea 0,52 mg depottabletter Pramipexol
English: Oprymea 0.52 mg prolonged-release tablets 10 prolonged-release tablets: EU/1/08/469/030 30 prolonged-release tablets: EU/1/08/469/031 90 prolonged-release tablets: EU/1/08/469/032 100 prolonged-release tablets: EU/1/08/469/033
Danish: Oprymea 0,52 mg depottabletter 10 depottabletter: EU/1/08/469/030 30 depottabletter: EU/1/08/469/031 90 depottabletter: EU/1/08/469/032 100 depottabletter: EU/1/08/469/033
English: Oprymea 1.57 mg prolonged-release tablets Pramipexole
Danish: Oprymea 1,57 mg depottabletter Pramipexol
English: Very common may affect more than 1 in 10 people Common may affect up to 1 in 10 people
Danish: Kan forekomme hos mellem 1 og 10 ud af 100 patienter Ikke almindelig Kan forekomme hos mellem 1 og 10 ud af 1000 patienter Sjælden
English: Oprymea 0.26 mg prolonged-release tablets 10 prolonged-release tablets: EU/1/08/469/026 30 prolonged-release tablets: EU/1/08/469/027 90 prolonged-release tablets: EU/1/08/469/028 100 prolonged-release tablets: EU/1/08/469/029
Danish: Oprymea 0,26 mg depottabletter 10 depottabletter: EU/1/08/469/026 30 depottabletter: EU/1/08/469/027 90 depottabletter: EU/1/08/469/028 100 depottabletter: EU/1/08/469/029
English: Oprymea 0.52 mg prolonged-release tablets
Danish: Oprymea 0,52 mg depottabletter
English: Each prolonged-release tablet contains 0.52 mg pramipexole (as 0.75 mg pramipexole dihydrochloride monohydrate).
Danish: Hver depottablet indeholder 0,52 mg pramipexol (som 0,75 mg pramipexoldihydrochloridmonohydrat).
English: Oprymea 0.26 mg prolonged-release tablets Each prolonged-release tablet contains 0.26 mg pramipexole (as 0.375 mg pramipexole dihydrochloride monohydrate).
Danish: Oprymea 0,26 mg depottabletter Hver depottablet indeholder 0,26 mg pramipexol (som 0,375 mg pramipexoldihydrochloridmonohydrat).
English: EU/1/08/469/030 [10 prolonged-release tablets] EU/1/08/469/031[30 prolonged-release tablets] EU/1/08/469/032[90 prolonged-release tablets] EU/1/08/469/033[100 prolonged-release tablets]
Danish: EU/1/08/469/030 [10 depottabletter] EU/1/08/469/031 [30 depottabletter] EU/1/08/469/032 [90 depottabletter] EU/1/08/469/033 [100 depottabletter]
English: Oprymea 1.05 mg prolonged-release tablets Pramipexole
Danish: Oprymea 1,05 mg depottabletter Pramipexol
English: Oprymea 2.1 mg prolonged-release tablets Pramipexole
Danish: Oprymea 2,1 mg depottabletter Pramipexol
English: Common may affect up to 1 in 10 people
Danish: Kan forekomme hos mellem 1 og 10 ud af 10.000 patienter
English: EU/1/08/469/038 [10 prolonged-release tablets] EU/1/08/469/039 [30 prolonged-release tablets] EU/1/08/469/040 [90 prolonged-release tablets] EU/1/08/469/041 [100 prolonged-release tablets]
Danish: EU/1/08/469/038 [10 depottabletter] EU/1/08/469/039 [30 depottabletter] EU/1/08/469/040 [90 depottabletter] EU/1/08/469/041 [100 depottabletter]
English: Treatment discontinuation
Danish: Behandlingsophør
English: In these cases Oprymea may affect your ability to drive and operate machinery.
Danish: Hvis du tager beroligende medicin og drikker alkohol, kan Oprymea påvirke din evne til at køre bil og håndtere maskiner.
English: White or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P3 on one side, with bevelled edges and possible spots.
Danish: Hvide til næsten hvide, runde (10 mm i diameter), let hvælvede tabletter, præget med P3 på den ene side, med skrå kanter og muligvis plettede.
English: EU/1/08/469/026 [10 prolonged-release tablets] EU/1/08/469/027 [30 prolonged-release tablets] EU/1/08/469/028 [90 prolonged-release tablets] EU/1/08/469/029 [100 prolonged-release tablets]
Danish: EU/1/08/469/026 [10 depottabletter] EU/1/08/469/027 [30 depottabletter] EU/1/08/469/028 [90 depottabletter] EU/1/08/469/029 [100 depottabletter]
English: White or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P4 on one side, with bevelled edges and possible spots.
Danish: Hvide til næsten hvide, runde (10 mm i diameter), let hvælvede tabletter, præget med P4 på den ene side, med skrå kanter og muligvis plettede.
English: White or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P1 on one side, with bevelled edges and possible spots.
Danish: Hvide til næsten hvide, runde (10 mm i diameter), let hvælvede tabletter, præget med P1 på den ene side, med skrå kanter og muligvis plettede.
English: 1 tablet Oprymea 0.088 mg 1 tablet Oprymea 1.1 mg three three times a day times a day
Danish: 1 tablet Oprymea 1,1 mg 3 gange om dagen
English: White or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P12 on one side, with bevelled edges and possible spots.
Danish: Hvide til næsten hvide, runde (10 mm i diameter), let hvælvede tabletter, præget med P12 på den ene side, med skrå kanter og muligvis plettede.
English: Oprymea 2.1 mg prolonged-release tablets
Danish: Oprymea 2,1 mg depottabletter
English: Oprymea 0.26 mg prolonged-release tablets Pramipexole
Danish: Oprymea 0,26 mg depottabletter Pramipexol
English: White or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P2 on one side, with bevelled edges and possible spots.
Danish: Hvide til næsten hvide, runde (10 mm i diameter), let hvælvede tabletter, præget med P2 på den ene side, med skrå kanter og muligvis plettede.
English: Oprymea 0.26 mg prolonged-release tablets Oprymea 0.52 mg prolonged-release tablets Oprymea 1.05 mg prolonged-release tablets
Danish: Oprymea 0,26 mg depottabletter Oprymea 0,52 mg depottabletter Oprymea 1,05 mg depottabletter
English: Uncommon: - Urge to behave in an unusual way* - Cardiac failure (heart problems which can cause shortness of breath or ankle swelling)* - Inappropriate antidiuretic hormone secretion* - Dyskinesia (e.g. abnormal, uncontrolled movements of the limbs) - Hyperkinesia (increased movements and inability to keep still)* - Paranoia (e.g. excessive fear for one's own well-being)* - Delusion* - Amnesia (memory disturbance)*
Danish: Ikke almindelig: - Trang til unormal adfærd* - Hjertesvigt (hjerteproblemer, der kan forårsage åndenød eller hævede ankler)* - Uhensigtsmæssig udskillelse af antidiuretisk hormon
English: Oprymea 0.26 mg prolonged-release tablets
Danish: Oprymea 0,26 mg depottabletter
English: What Oprymea looks like and contents of the pack Oprymea 0.26 mg prolonged-release tablets are white or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P1 on one side, with bevelled edges and possible spots.
Danish: Oprymea med 0,26 mg depottabletter er hvide til næsten hvide, runde (10 mm i diameter), let hvælvede tabletter, præget med P1 på den ene side, med skrå kanter og muligvis plettede.
English: Viread received a marketing authorisation valid throughout the EU on 5 February 2002.
Danish: Viread fik en markedsføringstilladelse med gyldighed i hele EU den 5. februar 2002.
English: Further information on Viread can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/viread.
Danish: Yderligere information om Viread findes på agenturets websted under: ema.europa.eu/medicines/human/EPAR/viread.
English: What is Viread and what is it used for?
Danish: Hvad er Viread, og hvad anvendes det til?
English: As for all medicines, data on the use of Viread are continuously monitored.
Danish: Som for alle lægemidler er data vedrørende brug af Viread løbende overvåget.
English: What measures are being taken to ensure the safe and effective use of Viread?
Danish: Hvilke foranstaltninger træffes der for at sikre risikofri og effektiv anvendelse af Viread?
English: Rare cases of severe kidney problems have also been seen in patients treated with Viread.
Danish: Sjældne tilfælde af svære nyreproblemer er også blevet konstateret hos patienter behandlet med Viread.
English: Viread is used in combination with other HIV medicines.
Danish: Viread anvendes i kombination med andre hivlægemidler.
English: An overview of Viread and why it is authorised in the EU
Danish: En oversigt over Viread, og hvorfor det er godkendt i EU
English: Side effects reported with Viread are carefully evaluated and any necessary action taken to protect patients.
Danish: Bivirkninger rapporteret for Viread vurderes omhyggeligt, og der tages de nødvendige forholdsregler for at beskytte patienterne.
English: Why is Viread authorised in the EU?
Danish: Hvorfor blev Viread godkendt i EU?
English: For more information about using Viread, see the package leaflet or contact your doctor or pharmacist.
Danish: For mere information om brug af Viread, se indlægssedlen, eller kontakt lægen eller apotekspersonalet.
English: The European Medicines Agency decided that Viread's benefits are greater than its risks and it can be authorised for use in the EU.
Danish: Det Europæiske Lægemiddelagentur konkluderede, at fordelene ved Viread opvejer risiciene, og at det kan godkendes til anvendelse i EU.
English: The dose may need to be reduced or the medicine given less often in patients who have moderately or severely reduced kidney function.
Danish: Dosis skal muligvis reduceres, eller lægemidlet gives mindre hyppigt, hos patienter, der har moderat eller svært nedsat nyrefunktion.
English: Moreover, Viread may cause a reduction in bone density.
Danish: Desuden kan Viread forårsage en reduktion i knoglevævstætheden.
English: Viread, taken in combination with other antiviral medicines, reduces the amount of HIV in the blood and keeps it at a low level.
Danish: Når Viread tages i kombination med andre antivirale lægemidler, nedsættes mængden af hiv i blodet og holdes på et lavt niveau.
English: For the treatment of HIV, Viread was more effective than placebo (a dummy treatment) when added to existing treatment.
Danish: Ved behandling af hiv var Viread mere effektivt end placebo (en uvirksom behandling), når det blev føjet til en eksisterende behandling.
English: What are the risks associated with Viread?
Danish: Hvilke risici er der forbundet med Viread?
English: Viread does not cure HIV infection or AIDS, but it may delay the damage to the immune system and the development of infections and diseases associated with AIDS.
Danish: Viread helbreder ikke hivinfektion eller aids, men kan sinke den skade på immunsystemet og de infektioner og sygdomme, der er forbundet med aids.
English: Other information about Viread:
Danish: Andre oplysninger om Viread
English: Viread stops the virus making DNA and prevents it from multiplying and spreading.
Danish: Viread forhindrer virusset i at danne DNA og forhindrer derved, at det formerer sig og spredes.
English: Although it showed no benefit of adding Viread to existing treatment compared with adding placebo, Viread produced similar levels of the active substance in the body compared to adults, and it was judged that the results were influenced by the type of patients included in the Viread group.
Danish: Selv om der ikke sås nogen fordel ved at føje Viread til en eksisterende behandling, når man sammenlignede med placebo, medførte Viread tilsvarende niveauer af det aktive stof i kroppen, når man sammenlignede med voksne, og det skønnedes, at resultaterne var påvirkede af typen af patienter i Viread-gruppen.
English: The company that makes Viread will ensure that all doctors who are expected to prescribe or use Viread in children are provided with educational materials containing important safety information, particularly on the risks and precautions relating to kidney function and the bones.
Danish: Virksomheden, der markedsfører Viread, vil sikre, at alle læger, som forventes at ordinere eller anvende lægemidlet til børn, får udleveret informationsmateriale, der indeholder sikkerhedsoplysninger, navnlig om risici og forholdsregler med hensyn til nyrefunktion og knogler.
English: Viread (tenofovir disoproxil)
Danish: Viread (tenofovirdisoproxil)
English: In children and adolescents it is only used in patients who cannot be treated with other first-line nucleotide reverse transcriptase inhibitors (NRTI).
Danish: Hos børn og unge anvendes det kun til patienter, der ikke kan førstevalgsbehandles med andre nukleotide reverse transkriptasehæmmere (NRTI).
English: The figure for the combination treatment of Viread and emtricitabine was 88%.
Danish: Ved kombinationsbehandlingen med Viread og emtricitabin var tallet 88 %.
English: In HIV infection, it blocks the activity of reverse transcriptase, an enzyme produced by HIV that allows it to infect cells and make more viruses.
Danish: Ved hivinfektion virker det ved at blokere revers transkriptase, et enzym, der produceres af hiv, så det kan inficere celler og producere flere virus.
English: The most common side effects with Viread (seen in more than 1 patient in 10) are nausea (feeling sick), vomiting, diarrhoea, dizziness, hypophosphataemia (low levels of phosphate in the blood), rash and asthenia (weakness).
Danish: De hyppigste bivirkninger ved Viread (som optræder hos mere end 1 ud af 10 patienter) er kvalme, opkastning, diarré, svimmelhed, hypofosfatæmi (lavt fosfatindhold i blodet), udslæt og asteni (svaghed).
English: Tenofovir also interferes with the action of an enzyme produced by the hepatitis B virus called DNA polymerase, which is involved in the formation of viral DNA.
Danish: Tenofovir påvirker også virkningsmekanismen hos et enzym produceret af hepatitis B-virusset kaldet "DNA-polymerase", som indgår i dannelsen af viralt DNA.
English: Tenofovir is a nucleotide reverse transcriptase inhibitor (NRTI).
Danish: Tenofovir er en nukleotid revers transkriptasehæmmer (NRTI).
English: The active substance in Viread, tenofovir disoproxil, is a ‘prodrug' that is converted into tenofovir in the body.
Danish: Det aktive stof i Viread, tenofovirdisoproxil, er et "prodrug", der i kroppen omdannes til tenofovir.
English: A study carried out in 87 adolescents (12 to 18 years of age) investigated the effects of adding Viread to existing treatment.
Danish: I et studie blandt 87 unge (i alderen 12-18 år) undersøgte man virkningerne af at føje Viread til en eksisterende behandling.
English: For patients who have taken medicines to treat HIV infection before, doctors should only prescribe Viread once they have looked at the antiviral medicines the patient has taken before or the likelihood that the virus will respond to antiviral medicines.
Danish: For så vidt angår patienter, der tidligere har fået lægemidler mod hivinfektion, skal lægen inden ordinering af Viread gennemgå de antivirale lægemidler, patienten tidligere har taget, og vurdere sandsynligheden for, at virusset reagerer på antivirale lægemidler.
English: Viread can only be obtained with a prescription and treatment should be started by a doctor who has experience in the treatment of HIV infection or chronic hepatitis B. Viread, available as tablets and as granules, is taken once a day with food.
Danish: Viread udleveres kun efter recept, og behandlingen bør iværksættes af en læge med erfaring i behandling af hivinfektion eller kronisk hepatitis B. Viread, der fås som tabletter og som granulat, tages én gang dagligt sammen med et måltid.
English: Viread is a medicine used to treat patients aged 2 years and above infected with human immunodeficiency virus type 1 (HIV 1), a virus that causes acquired immune deficiency syndrome (AIDS).
Danish: Viread er et lægemiddel, der anvendes til behandling af patienter i alderen 2 år og opefter, som er smittet med humant immundefektvirus type 1 (hiv-1), et virus, som forårsager erhvervet immundefektsyndrom (aids).
English: In adults, it can also be used for those patients with liver damage whose liver is not working properly (decompensated liver disease) and those patients who do not respond to treatment with lamivudine (another medicine for hepatitis B infection).
Danish: Hos voksne kan det også anvendes til patienter med leverskader, hvor leveren ikke fungerer korrekt (dekompenseret leversygdom), og til patienter, som ikke reagerer på behandling med lamivudin (et andet lægemiddel mod hepatitis B).
English: For the full list of side effects and restrictions with Viread, see the package leaflet.
Danish: Den fuldstændige liste over bivirkninger og begrænsninger ved Viread fremgår af indlægssedlen.
English: In a third study Viread was as effective as another medicine stavudine, when added to lamivudine and efavirenz.
Danish: I et tredje studie var Viread lige så effektivt som et andet lægemiddel, stavudin, når det blev føjet til lamivudin og efavirenz.
English: One of these studies involved patients with ‘HBeAg-negative' hepatitis B, a type that is more difficult to treat, while the other involved the more common ‘HBeAgpositive' hepatitis B. After 48 weeks, 71% of the HBeAg-negative and 67% of HBeAg-positive patients taking Viread had a complete response to treatment, compared with 49% and 12%, respectively, of the patients taking adefovir dipivoxil.
Danish: I det ene af disse studier indgik patienter med "HBeAg-negativ" hepatitis B, en type, der er vanskeligere at behandle, mens det andet vedrørte den mere almindelige "HBeAg-positive" hepatitis B. Efter 48 uger udviste 71 % af de HBeAg-negative og 67 % af de HBeAg-positive patienter, der tog Viread, en fuldstændig respons på behandlingen, sammenlignet med henholdsvis 49 % og 12 % af de patienter, der tog adefovirdipivoxil.
English: Viread contains the active substance tenofovir disoproxil.
Danish: Viread indeholder det aktive stof tenofovirdisoproxil.
English: Overall, 70% of patients taking Viread or entecavir had a viral load below 400 copies/ml.
Danish: Samlet set havde 70 % af de patienter, der tog Viread eller entecavir, en virusbelastning på under 400 kopier/ml.
English: Viread is also used to treat chronic (long-term) hepatitis B virus infection in adults and children aged 2 years and above with liver damage whose liver is still working properly (compensated liver disease).
Danish: Viread anvendes også til behandling af kronisk hepatitis B-virusinfektion hos voksne og hos børn fra 2 år og opefter med leverskader, hvor leveren stadig fungerer korrekt (kompenseret leversygdom).
English: How is Viread used?
Danish: Hvordan anvendes Viread?
English: It showed that the majority of those who switched treatment from stavudine or zidovudine maintained their low HIV blood levels on Viread (83% of children in the Viread group and 92% of those on stavudine or zidovudine had viral loads below 400 copies/ml after 48 weeks).
Danish: Det viste sig, at flertallet af dem, der skiftede fra behandling med stavudin eller zidovudin, bevarede deres lave niveau af hiv i blodet ved skift til Viread (83 % af børnene i Viread-gruppen og 92 % af dem, der tog stavudin eller zidovudin, havde en virusbelastning på under 400 kopier/ml efter 48 uger).
English: For the treatment of hepatitis B, two studies involving 641 adult patients compared Viread with another medicine, adefovir dipivoxil.
Danish: Ved behandling af hepatitis B blev der i to studier blandt 641 voksne patienter foretaget en sammenligning mellem Viread og et andet lægemiddel, adefovirdipivoxil.
English: 89% of patients taking Viread had a viral load below 400 copies/ml after 96 weeks of treatment, compared with 86% of patients taking the combination treatment of Viread and emtricitabine.
Danish: 89 % af de patienter, der tog Viread, havde en virusbelastning på under 400 kopier/ml efter 96 ugers behandling sammenlignet med 86 % af de patienter, der tog Viread og emtricitabin som kombinationsbehandling.
English: What benefits of Viread have been shown in studies?
Danish: Hvilke fordele viser studierne, at der er ved Viread?
English: In a third study involving 112 adults whose liver had stopped working properly (decompensated liver disease) Viread was compared with entecavir and a combination treatment of Viread and emtricitabine.
Danish: I et tredje studie, der omfattede 112 voksne, hvis lever var ophørt med at fungere korrekt (dekompenseret leversygdom), blev Viread sammenlignet med entecavir og en kombinationsbehandling med Viread og emtricitabin.
English: Similar numbers of patients in the Viread and stavudine groups had viral loads below 400 copies/ml after 48 weeks.
Danish: Et tilsvarende antal patienter i Viread- og stavudin-gruppen havde en virusbelastning på under 400 kopier/ml efter 48 uger.
English: Two studies involving 741 HIV-infected adults showed that Viread resulted in a fall in the levels of HIV in the blood (viral load) of around 75% after 4 and after 24 weeks, compared with a small rise or fall in viral load of around 5% in the patients taking placebo.
Danish: Af to studier blandt 741 hivsmittede voksne, fremgik det, at Viread medførte et fald i mængden af hiv i blodet (virusbelastningen) på ca. 75 % efter 4 og efter 24 uger sammenlignet med en lille stigning eller et lille fald i virusbelastningen på ca. 5 % hos de patienter, der tog placebo.
English: A study in 97 children (aged 2 to 12 years) treated with stavudine or zidovudine, compared the effects of switching their treatment to Viread with continuing previous treatment.
Danish: I et studie blandt 97 børn (i alderen 2-12 år), som blev behandlet med stavudin eller zidovudin, sammenlignede man virkningerne af at skifte til behandling med Viread med virkningerne af at fortsætte en hidtidig behandling.
English: A fourth study, involving 280 adults who had not responded to treatment with lamivudine, compared Viread alone with a combination treatment of Viread and emtricitabine.
Danish: I et fjerde studie blandt 280 voksne, som ikke havde responderet på behandling med lamivudin, blev Viread som enkeltstofbehandling sammenlignet med Viread og emtricitabin som kombinationsbehandling.